NIH R01 · 2025
ABSTRACT The rollout of two recently approved pre-erythrocytic malaria vaccines – RTS,S and R21 – is an important step in reducing the burden of malaria in highly vulnerable populations. However, strategies to optimize the effectiveness of these vaccines are needed to improve population level protection against childhood malaria and to hasten progress towards elimination. RTS,S is currently available and has been integrated into routine vaccine schedules in some areas, including our study sites in western Kenya. The efficacy of RTS,S is partial, short- lived, and varies widely according to age and geographic location. It is not clear why RTS,S induces protection in some individuals and not…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.